We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-13.57%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$241M
AUM Growth
-$120M
Cap. Flow
+$14.3M
Cap. Flow %
5.93%
Top 10 Hldgs %
81.75%
Holding
117
New
44
Increased
16
Reduced
22
Closed
31

Sector Composition

Rank Sector Weight
1 Miscellaneous 91.07%
2 Healthcare 8.45%
3 Technology 0.29%
4 Financials 0.15%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVGR
51
DELISTED
Avinger, Inc. Common Stock
AVGR
$236K 0.1%
+1,895
New +$401K
TEUM
52
DELISTED
Pareteum Corporation
TEUM
$236K 0.1%
+572,271
New +$341K
NBRV
53
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$211K 0.09%
1,470
-2,673
-65% -$818K
GNCA
54
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
$207K 0.09%
+1,201
New +$2.43K
MYO icon
55
Myomo
MYO
$49.9M
$184K 0.08%
+51,588
New +$382K
TRIL
56
PUT
DELISTED
Trillium Therapeutics Inc.
TRIL
$182K 0.08%
+451
New +$1.71K
ALT icon
57
PUT
Altimmune
ALT
$632M
$171K 0.07%
+534
New +$1.23K
HEPA
58
DELISTED
Hepion Pharmaceuticals
HEPA
$128K 0.05%
+73
New +$292K
HIND
59
Vyome Holdings
HIND
$14.5M
-1
Closed -$1.31M
ATNM icon
60
Actinium Pharmaceuticals
ATNM
$40.9M
$121K 0.05%
20,728
-88,463
-81% -$628K
QCLS
61
Q/C Technologies Inc
QCLS
$4.01M
$118K 0.05%
9
+4
+80% +$69.7K
ZSAN
62
DELISTED
Zosano Pharma Corporation
ZSAN
$114K 0.05%
+5,815
New +$195K
GNPX icon
63
PUT
Genprex
GNPX
$2.82M
0
BNBX
64
DELISTED
BNB PLUS CORP
BNBX
$106K 0.04%
+2
New +$121K
LFWD icon
65
ReWalk Robotics
LFWD
$20.8M
$99K 0.04%
2,735
+1,232
+82% +$128K
NURO
66
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$93K 0.04%
10,281
+2,296
+29% +$48.9K
BLCM
67
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$89K 0.04%
+18,927
New +$203K
EFOI icon
68
Energy Focus
EFOI
$17.5M
$88K 0.04%
+7,637
New +$143K
BNTC icon
69
Benitec Biopharma
BNTC
$395M
$85K 0.04%
847
-3,792
-82% -$443K
PALI icon
70
Palisade Bio
PALI
$345M
$76K 0.03%
26
-59
-69% -$255K
AMRN
71
CALL
Amarin Corp
AMRN
$292M
$75K 0.03%
9
-93
-91% -$30.9K
BLIN icon
72
Bridgeline Digital
BLIN
$11.8M
$73K 0.03%
110,000
CYTO
73
DELISTED
Altamira Therapeutics Ltd
CYTO
$72K 0.03%
224
-206
-48% -$101K
NVIV
74
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$55K 0.02%
+1,306
New +$185K
XBIO icon
75
Xenetic Biosciences
XBIO
$9.77M
$45K 0.02%
6,052
-20,498
-77% -$238K

Similar funds

Sabby Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sabby Management held 117 positions worth $241M, down 33% from $361M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Sabby Management deployed $14.3M of net new capital in Q1 2020, opening 44 new positions and adding to 16 existing holdings. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 34,410 shares worth $3.05M.

By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, down from 94% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was SPDR Gold Trust, an estimated $2.92M trimmed.

  • Sabby Management's largest Q1 2020 buy was State Street Health Care Select Sector SPDR ETF: 34,410 shares worth $3.05M.
  • Sabby Management added most to Outlook Therapeutics in Q1 2020, an estimated $2.36M increase.
  • Sabby Management's biggest Q1 2020 reduction was SPDR Gold Trust, cutting an estimated $2.92M.
  • Sabby Management fully exited Traws Pharma in Q1 2020, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 82% of its $241M portfolio in Q1 2020.
  • Sabby Management opened 44 new positions and closed 31 in Q1 2020.
  • Sabby Management's portfolio value fell 33% quarter-over-quarter to $241M.

Based on Sabby Management's 13F filing for Q1 2020, filed 15 May 2020.